Latest news
HER2 Mutations in NSCLC: Critical Risks of Outdated Terms - OncodailyOncodaily · Fri, 07 Aug 2026 16:43:17 GMTRisk Stratification and Treatment Selection in EGFR-Mutant NSCLC - onclive.comonclive.com · Thu, 06 Aug 2026 19:45:26 GMTBlack Diamond Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewswireGlobeNewswire · Wed, 05 Aug 2026 20:01:00 GMTBeyond the Approval: Operationalizing Zongertinib for HER2-Mutant Lung Cancer - Pharmacy TimesPharmacy Times · Wed, 05 Aug 2026 15:22:02 GMTOlomorasib Earns FDA Breakthrough Therapy in KRAS G12C+ Pancreatic Cancer - CancerNetworkCancerNetwork · Tue, 04 Aug 2026 15:38:44 GMTBlossomHill eyes $112M IPO harvest to fund Tagrisso challenger - Fierce BiotechFierce Biotech · Mon, 03 Aug 2026 13:18:47 GMTLilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of previously treated KRAS G12C-mutant advanced pancreatic cancer - PR NewswirePR Newswire · Mon, 03 Aug 2026 11:45:00 GMTHerbert Loong: EGFR-Mutant NSCLC Management in the Era of FLAURA2 and MARIPOSA - OncodailyOncodaily · Sun, 02 Aug 2026 20:14:50 GMT